Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system

Journal of the National Cancer Institute

Volumn 103, Issue 9, 2011, Pages 714-736

  Kohler, Betsy A ^a   Ward, Elizabeth ^b   McCarthy, Bridget J ^c   Schymura, Maria J ^a,d   Ries, Lynn A G ^e   Eheman, Christie ^f   Jemal, Ahmedin ^b   Anderson, Robert N ^g   Ajani, Umed A ^f   Edwards, Brenda K ^e  

^a North American Association of Central Cancer Registries   (United States)

^b AMERICAN CANCER SOCIETY   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d New York State Cancer Registry   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^g NATIONAL CENTER FOR HEALTH STATISTICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; BRAIN TUMOR; CANCER INCIDENCE; CANCER MORTALITY; CHILD; ETHNICITY; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NERVOUS SYSTEM TUMOR; PRESCHOOL CHILD; PRIORITY JOURNAL; RACE DIFFERENCE; SCHOOL CHILD;

ADULT; AGE DISTRIBUTION; BRAIN NEOPLASMS; CHILD; CONFOUNDING FACTORS (EPIDEMIOLOGY); CONTINENTAL POPULATION GROUPS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; INCIDENCE; MALE; MORTALITY; NEOPLASMS; NERVOUS SYSTEM NEOPLASMS; POPULATION DYNAMICS; REGISTRIES; SEER PROGRAM; SEX DISTRIBUTION; SURVIVAL RATE; UNITED STATES;

EID: 79955768010     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr077     Document Type: Article

References (121)

1. Wingo PA, Ries LA, Rosenberg HM, Miller DS, Edwards BK. Cancer incidence and mortality, 1973-1995: a report card for the U.S. Cancer. 1998;82(6):1197-1207. (Pubitemid 28136536)
2. Wingo PA, Ries LA, Giovino GA, et al. Annual report to the nation on the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking. J Natl Cancer Inst. 1999;91(8):675-690. (Pubitemid 29234561)
3. Ries LA, Wingo PA, Miller DS, et al. The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer. 2000;88(10):2398-2424. (Pubitemid 30247142)
4. Howe HL, Wingo PA, Thun MJ, et al. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst. 2001;93(11):824-842. (Pubitemid 32586611)
5. Edwards BK, Howe HL, Ries LA, et al. Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden. Cancer. 2002;94(10):2766-2792. (Pubitemid 34478095)
6. Weir HK, Thun MJ, Hankey BF, et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst. 2003;95(17):1276-1299. (Pubitemid 37160862)
7. Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer. 2004;101(1):3-27. (Pubitemid 38812419)
8. Edwards BK, Brown ML, Wingo PA, et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst. 2005;97(19):1407-1427. (Pubitemid 41520077)
9. Howe HL, Wu X, Ries LA, et al. Annual report to the nation on the status of cancer, 1975-2003, featuring cancer among U.S. Hispanic/Latino populations. Cancer. 2006;107(8):1711-1742. (Pubitemid 44582941)
10. Espey DK, Wu XC, Swan J, et al. Annual report to the nation on the status of cancer, 1975-2004, featuring cancer in American Indians and Alaska Natives. Cancer. 2007;110(10):2119-2152. (Pubitemid 350100734)
11. Jemal A, Thun MJ, Ries LA, et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst. 2008;100(23):1672-1694.
12. Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116(3):544-573.
13. Fritz A, Percy C, Jack A. International Classifcation of Diseases of Oncology. 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
14. Altekruse SF, Kosary CL, Krapcho M, et al., eds. SEER Cancer Statistics Review, 1975-2007. Bethesda, MD: National Cancer Institute; 2010. http:// seer.cancer.gov/csr/1975-2007, Accessed September 29, 2010.
15. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov).
16. SEER*Stat Database: Incidence-SEER 9 Regs and SEER 13 Regs Research Data, Nov 2009 Sub (1973-2007) and population estimate. http://seer.cancer.gov/ popdata/index.html
17. National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2010, based on the November 2009 submission. http://seer.cancer.gov/resources. Accessed September 20, 2010.
18. Central Brain Tumor Registry of the United States (CBTRUS). CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2006. Hinsdale, IL: Central Brain Tumor Registry of the United States; 2010.
19. Louis DN, Ohgaki H, Wiestler OD, Cavanee WK (eds). WHO Classifcation of Tumours of the Central Nervous System. Lyon, France: IARC; 2007.
20. Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classifcation of Childhood Cancer. 3rd ed. Cancer, 2005;103(7): 1457-1467.
21. Xu J, Kochanek KD, Murphy SL, Tejada-Vera B. Deaths: fnal data for 2007. Natl Vital Stat Rep. 2010;58(19):1-136.
22. World Health Organization. International Statistical Classifcation of Diseases and Related Health Problems. 10th rev. Geneva, Switzerland: World Health Organization; 1992.
23. World Health Organization. Manual of the International Statistical Classifcation of Diseases, Injuries, and Causes of Death, Adapted for Use in the United States. 6th rev. Geneva, Switzerland: World Health Organization; 1948.
24. World Health Organization. Manual of the International Statistical Classifcation of Diseases, Injuries, and Causes of Death, Adapted for Use in the United States. 7th rev. Geneva, Switzerland: World Health Organization; 1955.
25. US Department of Health, Education, and Welfare. Manual of the International Statistical Classifcation of Diseases, Injuries, and Causes of Death, Adapted for Use in the United States. 8th rev. Washington, DC: US Department of Health, Education, and Welfare, National Center for Health Statistics, Public Health Service; 1968.
26. World Health Organization. Manual of the International Statistical Classifcation of Diseases, Injuries, and Causes of Death, Based on the Recommendations of the Ninth Revision Conference, 1975. Geneva, Switzerland: World Health Organization; 1977.
27. Arias E, Schauman WS, Eschbach K, Sorlie PD, Backlund E. The validity of race and Hispanic origin reporting on death certifcates in the United States. Vital Health Stat 2. 2008;(148):1-23.
28. National Cancer Institute. Surveillance, Epidemiology and End Results (SEER) Program. Population Estimates Used in NCI's SEER*Stat Software.http://seer.cancer.gov/popdata/methods.html. Accessed March 8, 2011.
29. Centers for Disease Control and Prevention. National Center for Health Statistics. National Vital Statistics System. U.S. Census Populations With Bridged Race Categories.http://www.cdc.gov/nchs/nvss/bridged-race.htm. Accessed March 8, 2011.
30. Surveillance Research Program. National Cancer Institute SEER*Stat Software, version 6.6.2. Bethesda, MD: National Cancer Institute; 2010. http:// www.seer.cancer.gov/seerstat. Accessed September 20, 2010.
31. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for join-point regression with applications to cancer rates. Stat Med. 2000;19(3): 335-351. (Pubitemid 30070608)
32. Clegg LX, Feuer EJ, Midthune DN, Fay MP, Hankey BF. Impact of reporting delay and reporting error on cancer incidence rates and trends. J Natl Cancer Inst. 2002;94(20):1537-1545. (Pubitemid 35277277)
33. Clegg LX, Hankey BF, Tiwari R, Feuer EJ, Edwards BK. Estimating average annual per cent change in trend analysis. Stat Med. 2009;28(29): 3670-3682.
34. Harris JE. Cigarette smoking among successive birth cohorts of men and women in the United States during 1900-80. J Natl Cancer Inst. 1983; 71(3):473-479. (Pubitemid 13012122)
35. Burns DM, Lee L, Shen LZ, et al. Cigarette Smoking Behavior in the United States. Changes in Cigarette-Related Disease Risks and Their Implication for Prevention and Control. Bethesda, MD: National Institutes of Health, National Cancer Institute; Monograph 8. NIH Pub No. 97-4213; 1997.
36. Jemal A, Chu KC, Tarone RE. Recent trends in lung cancer mortality in the United States. J Natl Cancer Inst. 2001;93(4):277-283. (Pubitemid 32219814)
37. Jemal A, Ward E, Thun MJ. Contemporary lung cancer trends among U.S. women. Cancer Epidemiol Biomarkers Prev. 2005;14(3): 582-585. (Pubitemid 40489199)
38. Saraiya M, Glanz K, Briss PA, et al. Interventions to prevent skin cancer by reducing exposure to ultraviolet radiation: a systematic review. Am J Prev Med. 2004;27(5):422-466. (Pubitemid 39535360)
39. Bishop JN, Bataille V, Gavin A, et al. The prevention, diagnosis, referral and management of melanoma of the skin: concise guidelines. Clin Med. 2007;7(3):283-290. (Pubitemid 46998762)
40. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300.
41. Shao YH, Demissie K, Shih W, et al. Contemporary risk profle of prostate cancer in the United States. J Natl Cancer Inst. 2009;101(18): 1280-1283.
42. Andriole GL, Crawford ED, Grubb RL III, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13): 1310-1319.
43. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009; 360(13):1320-1328.
44. Tsodikov A, Szabo A, Wegelin J. A population model of prostate cancer incidence. Stat Med. 2006;25(16):2846-2866. (Pubitemid 44193388)
45. Etzioni R, Tsodikov A, Mariotto A, et al. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control. 2008;19(2):175-181.
46. Draisma G, Etzioni R, Tsodikov A, et al. Lead time and overdiagnosis in prostate-specifc antigen screening: importance of methods and context. J Natl Cancer Inst. 2009;101(6):374-383.
47. Holford TR, Cronin KA, Mariotto AB, Feuer EJ. Changing patterns in breast cancer incidence trends. J Natl Cancer Inst Monogr. 2006;(36):19-25.
48. DeSantis C, Howlader N, Cronin KA, Jemal A. Breast cancer incidence rates in US women are no longer declining [published online ahead of print Feb 28, 2011]. Cancer Epidemiol Biomarkers Prev. 2011; doi:10.1158/1055-9965.EPI-11- 0061.
49. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007;356(16): 1670-1674. (Pubitemid 46631679)
50. Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res. 2007;9(3):R28.
51. U.S. Preventive Services Task Force. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;151(10):716-726.
52. Nelson HD, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L. Screening for breast cancer: an update for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;151(10):727-737.
53. Kerlikowske K. Evidence-based breast cancer prevention: the importance of individual risk. Ann Intern Med. 2009;151(10):750-752.
54. Mandelblatt JS, Cronin KA, Bailey S. Effects of mammography screening under different screening schedules: model estimates of potential benefts and harms. Ann Intern Med. 2009;151(10):738-747.
55. Saslow D, Boetes C, Burke W, et al.; American Cancer Society Breast Cancer Advisory Group. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57(2):75-89. (Pubitemid 46535708)
56. Erratum in: CA Cancer J Clin. 2007;57(3):185.
57. Smith RA, Saslow D, Sawyer KA, et al.; American Cancer Society High-Risk Work Group, American Cancer Society Screening Older Women Work Group, American Cancer Society Mammography Work Group, American Cancer Society Physical Examination Work Group, American Cancer Society New Technologies Work Group, American Cancer Society Breast Cancer Advisory Group. American Cancer Society guidelines for breast cancer screening: update 2003. CA Cancer J Clin. 2003;53(3):141-169. (Pubitemid 36722306)
58. Garber JE. Breast cancer screening: a fnal analysis? CA Cancer J Clin. 2003;53(3):138-140. (Pubitemid 36722305)
59. Smith MA, Seibel NL, Altekruse SF, et al. Outcomes for children and adolescents with cancer: challenges for the twenty-frst century. J Clin Oncol. 2010;28(15):2625-2634.
60. American Cancer Society. Cancer Facts & Figures 2010. Atlanta, GA: American Cancer Society 2010.
61. Sloane D. Cancer epidemiology in the United States: racial, social, and economic factors. Methods Mol Biol. 2009;(471):65-83.
62. Legler JM, Ries LA, Smith MA, et al. Cancer surveillance series [corrected]: brain and other central nervous system cancers: recent trends in incidence and mortality. J Natl Cancer Inst. 1999;91(16):1382-1390. (Pubitemid 29399996)
63. DeAngelis LM. Brain tumors. N Engl J Med. 2001;344(2):114-123.
64. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008; 359(5):492-507.
65. McCarthy BJ, Propp JM, Davis FG, Burger PC. Time trends in oligoden-droglial and astrocytic tumor incidence. Neuroepidemiology. 2008;30(1):34-44. (Pubitemid 351311724)
66. Cairncross JG, Ueki K, Zlatescu MC, et al. Specifc genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligo-dendrogliomas. J Natl Cancer Inst. 1998;90(19):1473-1479. (Pubitemid 28482012)
67. Kadan-Lottick NS, Skluzacek MC, Gurney JG. Decreasing incidence rates of primary central nervous system lymphoma. Cancer. 2002;95(1): 193-202. (Pubitemid 34743498)
68. Prados MD. Primary neoplasms of the central nervous system in adults. In: Kufe DW, Bast RC Jr, Hait W, et al., eds. Cancer Medicine. 7th ed. Hamilton, ON: BC Decker; 2006.
69. Kirsch DG, Tarbell NJ. Conformal radiation therapy for childhood CNS tumors. Oncologist. 2004;9(4):442-450. (Pubitemid 39014555)
70. Packer RJ. Childhood brain tumors: accomplishments and ongoing challenges. J Child Neurol. 2008;23(10):1122-1127.
71. Neglia JP, Robison LL, Stovall M, et al. New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2006;98(21): 1528-1537. (Pubitemid 44680904)
72. Merchant TE, Pollack IF, Loeffer JS. Brain tumors across the age spectrum: biology, therapy, and late effects. Semin Radiat Oncol. 2010;20(1):58-66.
73. Connelly JM, Malkin MG. Environmental risk factors for brain tumors. Curr Neurol Neurosci Rep. 2007;7(3):208-214. (Pubitemid 46831514)
74. Davis FS. Epidemiology of brain tumors. Expert Rev Anticancer Ther. 2007;7(12 suppl):S3-S6.
75. Fisher JL, Schwartzbaum JA, Wrensch M, Wiemels JL. Epidemiology of brain tumors. Neurol Clin. 2007;25(4):867-890, vii. (Pubitemid 47603275)
76. Bondy ML, Scheurer ME, Malmer B, et al.; Brain Tumor Epidemiology Consortium. Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer. 2008;113(7 suppl):1953-1968.
77. Ohgaki H. Epidemiology of brain tumors. Methods Mol Biol. 2009; 472:323-342.
78. Gu J, Liu Y, Kyritsis AP, Bondy ML. Molecular epidemiology of primary brain tumors. Neurotherapeutics. 2009;6(3):427-435.
79. Liu Y, Shete S, Hosking F, Robertson L, Houlston R, Bondy M. Genetic advances in glioma: susceptibility genes and networks. Curr Opin Genet Dev. 2010;20(3):239-244.
80. Liu Y, Shete S, Hosking FJ, Robertson LB, Bondy ML, Houlston RS. New insights into susceptibility to glioma. Arch Neurol. 2010;67(3): 275-278.
81. Wiemels J, Wrensch M, Claus EB. Epidemiology and etiology of menin-gioma. J Neurooncol. 2010;99(3):307-314.
82. Hill DA, Inskip PD, Shapiro WR, et al. Cancer in frst-degree relatives and risk of gliomas in adults. Cancer Epidemiol Biomarkers Prev. 2003; 12(12):1443-1448. (Pubitemid 38031747)
83. Hemminki K, Li X. Familial risks in nervous system tumors. Cancer Epidemiol Biomarkers Prev. 2003;12(11, pt 1):1137-1142. (Pubitemid 37499435)
84. Wrensch M, Lee M, Miike R, et al. Familial and personal medical history of cancer and nervous system conditions among adults with glioma and controls. Am J Epidemiol. 1997;145(7):581-593. (Pubitemid 27154860)
85. Hemminki K, Tretli S, Olsen JH, et al. Familial risks in nervous system tumours: joint Nordic study. Br J Cancer. 2010;102(12):1786-1790.
86. Wiemels JL, Wilson D, Patil C, et al. IgE, allergy, and risk of glioma: update from the San Francisco Bay Area Adult Glioma Study in the temo-zolomide era. Int J Cancer. 2009;125(3):680-687.
87. Il'yasova D, McCarthy B, Marcello J, et al. Association between glioma and history of allergies, asthma, and eczema: a case-control study with three groups of controls. Cancer Epidemiol Biomarkers Prev. 2009;18(4): 1232-1238.
88. Brenner AV, Linet MS, Fine HA, et al. History of allergies and autoimmune diseases and risk of brain tumors in adults. Int J Cancer. 2002; 99(2):252-259. (Pubitemid 34309483)
89. Ryan P, Lee MW, North B, McMichael AJ. Risk factors for tumors of the brain and meninges: results from the Adelaide Adult Brain Tumor Study. Int J Cancer. 1992;51(1):20-27.
90. Cicuttini FM, Hurley SF, Forbes A, et al. Association of adult glioma with medical conditions, family and reproductive history. Int J Cancer. 1997; 71(2):203-207. (Pubitemid 27252991)
91. Hochberg F, Toniolo P, Cole P, Salcman M. Nonoccupational risk indicators of glioblastoma in adults. J Neurooncol. 1990;8(1):55-60. (Pubitemid 20117354)
92. Schlehofer B, Blettner M, Becker N, Martinsohn C, Wahrendorf J. Medical risk factors and the development of brain tumors. Cancer. 1992;69(10):2541-2547.
93. Schoemaker MJ, Swerdlow AJ, Hepworth SJ, McKinney PA, van Tongeren M, Muir KR. History of allergies and risk of glioma in adults. Int J Cancer. 2006;119(9):2165-2172. (Pubitemid 44423676)
94. Wiemels JL, Wiencke JK, Sison JD, Miike R, McMillan A, Wrensch M. History of allergies among adults with glioma and controls. Int J Cancer. 2002;98(4):609-615. (Pubitemid 34208564)
95. Wigertz A, Lonn S, Schwartzbaum J, et al. Allergic conditions and brain tumor risk. Am J Epidemiol. 2007;166(8):941-950. (Pubitemid 47511691)
96. Schlehofer B, Blettner M, Preston-Martin S, et al. Role of medical history in brain tumour development. Results from the International Adult Brain Tumour Study. Int J Cancer. 1999;82(2):155-160.
97. Schwartzbaum J, Jonsson F, Ahlbom A, et al. Cohort studies of association between self-reported allergic conditions, immune-related diagnoses and glioma and meningioma risk. Int J Cancer. 2003;106(3): 423-428. (Pubitemid 36870407)
98. Turner MC, Chen Y, Krewski D, Ghadirian P, Thun MJ, Calle EE. Cancer mortality among US men and women with asthma and hay fever. Am J Epidemiol. 2005;162(3):212-221. (Pubitemid 41373525)
99. Berg-Beckhoff G, Schüz J, Blettner M, et al. History of allergic disease and epilepsy and risk of glioma and meningioma (INTERPHONE study group, Germany). Eur J Epidemiol. 2009;24(8):433-440.
100. Linos E, Raine T, Alonso A, Michaud D. Atopy and risk of brain tumors: a meta-analysis. J Natl Cancer Inst. 2007;99(20):1544-1550. (Pubitemid 351767237)
101. Schoemaker MJ, Swerdlow AJ, Hepworth SJ, van Tongeren M, Muir KR, McKinney PA. History of allergic disease and risk of meningioma. Am J Epidemiol. 2007;165(5):477-485. (Pubitemid 46340556)
102. Ahlbom A, Feychting M, Green A, Kheifets L, Savitz DA, Swerdlow AJ; ICNIRP (International Commission for Non-Ionizing Radiation Protection) Standing Committee on Epidemiology. Epidemiologic Evidence on Mobile Phones and Tumor Risk: A Review. Stockholm, Sweden: Department of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet; 2009.
103. Kundi M. The controversy about a possible relationship between mobile phone use and cancer. Environ Health Perspect. 2009;117(3):316-324.
104. Khurana VG, Teo C, Kundi M, Hardell L, Carlberg M. Cell phones and brain tumors: a review including the long-term epidemiologic data. Surg Neurol. 2009;72(3):205-214.
105. Han YY, Kano H, Davis DL, Niranjan A, Lunsford LD. Cell phone use and acoustic neuroma: the need for standardized questionnaires and access to industry data. Surg Neurol. 2009;72(3):216-222.
106. Inskip PD, Hoover RN, Devesa SS. Brain cancer incidence trends in relation to cellular telephone use in the United States. NeuroOncol. 2010; 12(11):1147-1151.
107. Howlader N, Ries LA, Stinchcomb DG, Edwards BK. The impact of underreported Veterans Affairs data on national cancer statistics: analysis using population-based SEER registries. J Natl Cancer Inst. 2009; 101(7):533-536.
108. Miller BA, Chu KC, Hankey BF, Ries LA. Cancer incidence and mortality patterns among specifc Asian and Pacifc Islander populations in the U.S. Cancer Causes Control. 2008;19(3):227-256.
109. Howe HL, Lake A, Schymura MJ, Edwards BK. Indirect method to estimate specifc Hispanic group cancer rates. Cancer Causes Control. 2009;20(7):1215- 1226.
110. Espey DK, Wiggins C, Jim MA, Miller BA, Johnson CJ, Becker TM. Methods for improving cancer surveillance data in American Indian and Alaska Native Populations. Cancer. 2008;113(S5):1120-1130.
111. Wingo PA, Tucker TC, Jamison PM, et al. Cancer in Appalachia, 2001-2003. Cancer. 2008;112(1):181-192.
112. Lengerich EJ, Tucker TC, Powell RK, et al. Cancer incidence in Kentucky, Pennsylvania, and West Virginia: disparities in Appalachia. J Rural Health. 2005;21(1):39-47. (Pubitemid 40052512)
113. Becker TM, Espey DK, Lawson HW, Saraiya M, Jim MA, Waxman AG. Regional differences in cervical cancer incidence among American Indians and Alaska Natives, 1999-2004. Cancer. 2008;113(5 suppl): 1234-1243.
114. Rajaraman P, Brenner AV, Butler MA, et al. Common variation in genes related to innate immunity and risk of adult glioma. Cancer Epidemiol Biomarkers Prev. 2009;18(5):1651-1658.
115. McKean-Cowdin R, Barnholtz-Sloan J, Inskip PD, et al. Associations between polymorphisms in DNA repair genes and glioblastoma. Cancer Epidemiol Biomarkers Prev. 2009;18(4):1118-1126.
116. Kiuru A, Lindholm C, Heinävaara S, et al. XRCC1 and XRCC3 variants and risk of glioma and meningioma. J Neurooncol. 2008;88(2):135-142.
117. Malmer B, Adatto P, Armstrong G, et al. GLIOGENE an International Consortium to Understand Familial Glioma. Cancer Epidemiol Biomarkers Prev. 2007;16(9):1730-1734. (Pubitemid 47450501)
118. Moore HM, Compton CC, Lim MD, Vaught J, Christiansen KN, Alper J. 2009 Biospecimen research network symposium: advancing cancer research through biospecimen science. Cancer Res. 2009;69(17):6770-6772.
119. Khleif SN, Doroshow JH, Hait WN; AACR-FDA-NCI Cancer Biomarkers Collaborative. AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development. Clin Cancer Res. 2010;16(13):3299-3318.
120. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defnes human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061-1068.
121. US Census Bureau. US Population Projections. Table 5: Population under age 18 and 65 and older: 2000, 2010, and 2030.US Census Bureau/US Population Projections Web site. http://www.census.gov/population /www/projections/ projectionsagesex.html. Accessed March 8, 2011.